Videos

Utilizing Pathways for Diagnosis, Treatment, and Survivorship in Cancer Care

10/15/2022

Tatjana Kolevska, MD, Kaiser Permanente, presents at the 2022 Oncology Clinical Pathways Congress the importance of connecting all specialties in pathways, meaning screening, diagnosis, treatment, and survivorship, for consistent and up to date care.

Current Issue

August 2024

Volume 10

Issue 4

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Recent Stories

News

Study Examines Impact of Vial Sizes on Drug Waste of Multiple Myeloma Treatment

09/06/2024

Grace Taylor , MS, MA;

Researchers looked at the impact of vial sizes on drug waste and cost when using bortezomib and carfilzomib to treat patients with multiple myeloma.

Researchers looked at the impact...

09/06/2024

Journal of Clinical Pathways

News

Evaluating Stereotactic Radio Surgery Plus TKI Vs TKI Alone Among Patients With Brain Metastases from EGFR- and ALK-Altered NSCLC (Part I)

09/05/2024

Luke R.G. Pike , MD, PhD;

Luke Pike, MD, breaks down the TURBO-Non–Small Cell Lung Cancer study and summarizes the main findings.

Luke Pike, MD, breaks down the...

09/05/2024

Journal of Clinical Pathways

Videos

Safety and Efficacy of Osimertinib Plus Consolidative Stereotactic Ablative Radiation in Patients With Advanced EGFR Mutant NSCLC

08/28/2024

Sawsan Rashdan , MD;

Sawsan Rashdan, MD, shares the main findings from her study on the use of osimertinib plus consolidative stereotactic ablative radiation for treating patients with advanced EGFR-mutated non–small cell lung cancer (NSCLC).

Sawsan Rashdan, MD, shares the...

08/28/2024

Journal of Clinical Pathways

Videos

Treatment Options for Chronic Lymphocytic Leukemia Beyond Chemotherapy

08/26/2024

Matthew Cortese , MD, MPH;

Matthew Cortese, MD, discusses recent updates in the National Comprehensive Cancer Network guidelines for the treatment of chronic lymphocytic leukemia (CLL) and ongoing clinical trials in this space.

Matthew Cortese, MD, discusses...

08/26/2024

Journal of Clinical Pathways

Abstracts

Clinical Benefits and Commonly Reported Adverse Events and Their Associated Costs in Patients With Chronic Lymphocytic Leukemia Treated With Bruton Tyrosine Kinase Inhibitors in First-Line and Relapsed/Refractory Settings

08/23/2024

Ibrutinib, acalabrutinib, and zanubrutinib are Bruton tyrosine kinase inhibitors (BTKis) approved for treatment of chronic lymphocytic leukemia (CLL). In this study, researchers used data from package inserts, clinical trials, and real-world...

Ibrutinib, acalabrutinib, and...

08/23/2024

Journal of Clinical Pathways

Utilizing Pathways for Diagnosis, Treatment, and Survivorship in Cancer Care

Current Issue

Special Reports

Subscribe

Recent Stories

Specialties

Events

Year Round Education

HMP Global Products